AplusB: A web application for investigating A + B designs for phase I cancer clinical trials

Graham M. Wheeler, Michael J. Sweeting, Adrian P. Mander

Research output: Contribution to journalArticlepeer-review

8 Citations (Scopus)


In phase I cancer clinical trials, the maximum tolerated dose of a new drug is often found by a dose-escalation method known as the A + B design. We have developed an interactive web application, AplusB, which computes and returns exact operating characteristics of A + B trial designs. The application has a graphical user interface (GUI), requires no programming knowledge and is free to access and use on any device that can open an internet browser. A customised report is available for download for each design that contains tabulated operating characteristics and informative plots, which can then be compared with other dose-escalation methods. We present a step-by-step guide on how to use this application and provide several illustrative examples of its capabilities.

Original languageEnglish
Article numbere0159026
JournalPLoS ONE
Issue number7
Publication statusPublished - Jul 2016
Externally publishedYes

Bibliographical note

Funding Information:
The authors would like to thank the Editor and three anonymous reviewers for their comments and suggestions, which have greatly improved this article. G.M. Wheeler and A.P. Mander are supported by the UK Medical Research Council (grant number G0800860). M.J. Sweeting is supported by a European Research Council Advanced Investigator Award: EPIC-Heart (grant number 268834), the UK Medical Research Council (grant number MR/L003120/1), the British Heart Foundation and the Cambridge National Institute for Health Research Biomedical Research Centre.

Publisher Copyright:
© 2016 Wheeler et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Dive into the research topics of 'AplusB: A web application for investigating A + B designs for phase I cancer clinical trials'. Together they form a unique fingerprint.

Cite this